A Locke Lord team represented Biohaven Pharmaceutical Holding Company Ltd. in its completion of the second tranche of its previously disclosed $80 million private financing. The financing was led by Venrock along with other leading biotech investors, including Vivo Capital, RA Capital Management, Aisling Capital, Rock Springs Capital, John W. Childs, Greg Bailey, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations and Litmore Capital. All investors who participated in the first tranche also participated in the second tranche. For more information, please see the Biohaven press release. The Locke Lord team was led by Douglas Gray (Providence) with assistance from Tamer Tullgren (Chicago) and Ralph Loren (Boston).
Posted March 10, 2017